Adam D. DeVore

Jan 2, 2024 | jacc.org | David A. Morrow |Eric Velazquez |Akshay S. Desai |Adam D. DeVore

References1. "Angiotensin-neprilysin inhibition versus enalapril in heart failure". N Engl J Med . 2014;371:993-1004. 2. "Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction". N Engl J Med . 2019;381:1609-1620. 3. "Rationale, design and baseline characteristics of the PARAGLIDE-HF trial: sacubitril/valsartan vs valsartan in HFmrEF and HFpEF with a worsening heart failure event". J Card Fail . 2023;29:922-930. 4.

Mar 24, 2023 | medscape.com | Ileana L. Piña |Adam D. DeVore

Recorded March 4, 2023. This transcript has been edited for clarity. Ileana L. Piña, MD, MPH: Hello. This is Ileana Piña. I'm at Thomas Jefferson University, and this is my blog. I am thrilled today to have one of my good friends here with me, Dr Adam DeVore, who's the director of transplant at Duke University. There's been conversation about heart donations, and as most of you know, the hearts are not sitting on the shelf.